You are here

Our science / Clinical Trials / Find a Trial / NCT00673049

Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer

Back to Search Print Save as PDF Bookmark Trial

NCT00673049

Last updated on February 28, 2019
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Fort Smith, Arkansas, 72903 United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Large Cell Carcinoma, Non-Small-Cell Lung Carcinoma, Squamous Cell Carcinoma, Adenosquamous Cell Carcinoma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Non small cell lung cancer with a primary histology of squamous cell, large cell or
adenosquamous carcinoma. At least 1 measurable lesion, as defined by RECIST.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Primary NSCLC adenocarcinoma and its subtypes or unknown/unspecified histology.

- Prior Erlotinib therapy.

- Prior anti IGF IR based investigational therapy.

NCT00673049
Pfizer
Terminated
Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Advanced Search

Based on your search, you may also be interested in

Non-Small-Cell Lung Carcinoma
A Study of Lorlatinib in ALK Inhibitor‑Treated ALK‑Positive NSCLC in China
NCT03909971
All Genders
18+
Years
Multiple Sites
Non-Small-Cell Lung Carcinoma
A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
NCT03052608
All Genders
18+
Years
Multiple Sites
Breast Neoplasms, Stomach Neoplasms, Esophagogastric Junction Neoplasm, Non-small-cell Lung Carcinoma
PF-06804103 Dose Escalation in HER2 Positive Solid Tumors
NCT03284723
All Genders
18+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now